300
Participants
Start Date
December 6, 2021
Primary Completion Date
December 1, 2031
Study Completion Date
February 1, 2032
Infigratinib
Infigratinib minitablets or sprinkle capsules to be administered by mouth. In subjects that completed a prior study with infigratinib, the starting dose will be the same as the last dose received in the prior interventional study with infigratinib. Infigratinib dose may be adjusted to 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
Infigratinib
Infigratinib sprinkle capsules to be administered by mouth. Starting dose for the subjects naïve to Infigratinib will be 0.25 mg/kg/day (the dose selected to be explored further in the dose escalation portion of Phase 2 study QBGJ398-201 (PROPEL 2)).
Murdoch Children's Hospital, Parkville
Haukeland University Hospital, Bergen
Nemours Alfred I. Dupont Hospital for Children, Wilmington
Johns Hopkins University, Baltimore
Hospital Universitario La Paz, Madrid
Hospital Universitario Virgen de la Victoria, Málaga
Hopital des Enfants, Toulouse
Vanderbilt University Medical Center, Nashville
Cincinnati Children's Hospital Medical Center, Cincinnati
University Hospital and UW Health Clinics, Madison
University of Missouri, Columbia
Hopital Femme Mere Enfant, Lyon
Hopital Necker-Enfants Malades, Paris
Children's Hospital Colorado, Aurora
USCF Benioff Children's Hospital, Oakland, Oakland
KK Women's and Children's Hosptial, Singapore
Hospital de Pediatría SAMIC Prof. Dr. Juan P. Garrahan, Ciudad Autonoma Buenos Aires
Stollery Children's Hospital, Edmonton
Children's Hospital - London Health Sciences Centre, London
Children's Hospital of Eastern Ontario, Ottawa
Centre Hospitalier Universitaire Sainte-Justine, Montreal
Oslo University Hospital, Oslo
Hospital Vithas San José, Vitoria-Gasteiz
Birmingham Women's and Children's NHS Foundation Trust, Birmingham
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol
Queen Elizabeth University Hospital, Glasgow
St. Thomas' Hospital, London
Manchester University Children's Hospital, Manchester
Sheffield Children's Hospital, Sheffield
QED Therapeutics, Inc., a Bridgebio company
INDUSTRY